Ethris Raises $26.3 Million Series B To Advance Pipeline Of Mrna-Based Therapeutics For Respiratory Diseases
Ethris Raises $26.3 Million Series B To Advance Pipeline Of Mrna-Based Therapeutics For Respiratory Diseases
02/01/22, 10:00 AM
Location
munichMoney raised
$26.3 million
Round Type
series b
Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (€23.3 Million) in a Series B financing round led by Laureus Capital. The proceeds of the Series B will advance the company’s lead programs ETH47 - a broad anti-viral immune modulator - and ETH42 - a protein-replacement therapy for primary ciliary dyskinesia (PCD) - into clinical studies, further advance its proprietary and differentiated mRNA and lipidoid nanoparticle (LNP) delivery platforms and increase its manufacturing capabilities. In conjunction with the financing, Dr. Christian Wawrzinek, Founder of Laureus Capital, will join Ethris as Managing Director and Chief Corporate Strategy Officer and support Ethris with a range of activities including corporate strategy, operational planning, and long-term growth opportunities.
Company Info
Location
munich, bavaria, germany
Additional Info
Ethris has paved a new path from genes to therapeutic proteins, using its proprietary messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilised mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines against viral infections, with the ultimate goal of improving patients' lives.